CMN-005 by CoImmune for Follicular Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Follicular Lymphoma.

City of Hope cures oldest person of blood cancer and achieves HIV remission

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a

February 16, 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a

October 16, 2024

One-time prime editing targets common genetic cause of cystic fibrosis

Researchers optimized prime editing for the efficient correction of the cystic fibrosis transmembrane conductance regulator F508del mutation in human airway epithelial cells, achieving high correction

July 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.